Association Pushes for Affordable Biopharmaceuticals

Published Online: Friday, April 1, 2005

The Generic Pharmaceutical Association (GPhA) applauded the FDA for confirming the science underlying generic biopharmaceuticals and moving closer to creating definitive requirements to approve these medicines. The green light for generic biopharmaceuticals would yield a significant cost savings.

"There is no reason to delay consumer access to affordable medicines when sound science supports the approval of biopharmaceuticals under a shortened and less costly pathway,"said Kathleen Jaeger, president and chief executive officer of GPhA, during an FDA-Drug Information Association public discussion on the issue. "It is possible to permit approval and marketing of a vast array of biopharmaceuticals with relatively low-to-modest complexity, and to expand that system in the coming years to permit the approval of more complex products,"she added.

Statistics support the economic need for more affordable versions of biopharmaceuticals. Currently, available biopharmaceutical products account for ~$30 billion in US sales and 12% of total pharmaceuticals. The figure is expected to more than double in 2010, with sales exceeding $60 billion. Because of their high costs, biopharmaceuticals will use a higher percentage of health care expenditures in the future and significantly burden health care purchasers, including employers and consumers.



Latest Articles
Medication errors injure thousands of patients annually, and while mistakes occur with all medication classes, those involving antiretroviral therapies are particularly troublesome.
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
Latest Issues
$auto_registration$
VSEO N/A